FDA Reduces Clinical Hold on Tekmira’s Experimental Ebola Drug

Drug Industry Daily
A A
The FDA has downgraded its clinical hold on Tekmira Pharmaceuticals’ TKM-Ebola experimental RNA interference therapeutic, a move that could clear the way for the drug’s potential use in individuals infected with Ebola virus.

To View This Article:

Login

Subscribe To Drug Industry Daily